Avastin meets goal in second Phase III trial in ovarian cancer
This article was originally published in Scrip
Executive Summary
Roche's Avastin (bevacizumab) has prolonged progression-free survival (PFS) in its second Phase III trial in newly diagnosed ovarian cancer, ICON7, which could lend support to the drug in this indication.